Search Medical Condition
Please enter condition
Please choose location from dropdown

Milford, Connecticut Clinical Trials

A listing of Milford, Connecticut clinical trials actively recruiting patient volunteers.

RESULTS

Found (521) clinical trials

Long Duration Therapeutic Ultrasound on Tendon Injuries

The ability of long duration therapeutic ultrasound to reduce pain, increase strength, and improve quality of life for patients with tendon injury [e.g. tendinopathy of the elbow (medial or lateral], Achilles tendon, or patellar tendon) will be assessed. During the 7-week protocol, participants will receive 4 continuous hours of therapy ...

Phase N/A

0.54 miles

Learn More »

A Clinical Trial of KT07 Capsule in the U.S.A

The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.

Phase

0.54 miles

Learn More »

A Virtual Reality Videogame for E-cigarette Prevention in Teens

Specific Aim #1: DEVELOPMENT: The researcher will update our current smokeSCREEN VR prototype into a polished videogame intervention using input from 4 focus groups of 5 adolescents each (n = 20), aged 12-17 and the extant literature. These focus groups will inform the development of the VR videogame intervention, smokeSCREEN ...

Phase N/A

0.54 miles

Learn More »

Alternative Schedule Study For VLA15 a Vaccine Candidate Against Lyme Borreliosis

This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study. A total of 250 healthy subjects,aged 18 to 65 years, will be randomized 2:2:1 to receive either VLA15 with Alum (two different dose levels) or Placebo. ...

Phase

0.54 miles

Learn More »

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis in Healthy Adults Aged 18 to 65 Years. Randomized Controlled Observer-blind Phase 2 Study.

This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study. In the Run-in phase, a total of 120 subjects aged 18 to 40 years will be randomized 1:1:1:1 to receive one of three VLA15 doses (VLA15 low dose, VLA15 medium dose, VLA15 high dose) or Placebo (30 subjects per ...

Phase

0.54 miles

Learn More »

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

The main purpose of this study is to compare the effects of semaglutide (Ozempic) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide ...

Phase

0.54 miles

Learn More »

S1613 Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and pertuzumab (TP) (Arm 1) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm (Arm 2) of cetuximab and irinotecan hydrochloride (irinotecan) (CETIRI). SECONDARY OBJECTIVES: I. To evaluate the overall response rate ...

Phase

4.08 miles

Learn More »

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients treated with durvalumab (MEDI4736) plus tremelimumab. SECONDARY OBJECTIVES: I. To estimate the duration of response (DoR) among patients who achieve a complete response (CR) ...

Phase

4.08 miles

Learn More »

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the objective response rates (ORR) stratified by BROCA-HR biomarker status. (Phase ...

Phase

4.08 miles

Learn More »

Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

PRIMARY OBJECTIVES: I. To compare the invasive disease-free survival (IDFS) in triple-negative breast cancer (TNBC) patients with residual basal-like disease after neoadjuvant chemotherapy who are randomized to post-preoperative platinum based chemotherapy with those who are randomized to capecitabine. SECONDARY OBJECTIVES: I. To evaluate overall survival (OS) and response-free survival (RFS) ...

Phase

4.08 miles

Learn More »